Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2

Pfizer announced that they've started testing the safety profile of their novel oral antiviral investigational drug candidate for SARS-CoV-2 infections.

Read the full article.